State of the art paper
Sorafenib in progressive castrate-resistant prostate cancer. Can we talk about a new therapeutic option?
More details
Hide details
Submission date: 2010-09-12
Final revision date: 2011-02-16
Acceptance date: 2011-03-24
Online publication date: 2012-07-04
Publication date: 2012-06-30
Arch Med Sci 2012;8(3):528-532
Castrate-resistant prostate cancer represents a significant clinical challenge. Currently, the standard treatment for patients with castrate-resistant prostate cancer is chemotherapy, after which patients only receive symptomatic treatment. The available results of phase II clinical trials of sorafenib in patients with hormone-refractory prostate cancer indicate that, despite a relatively short progression-free survival, the treatment may be associated with good outcomes in terms of overall survival and maintenance of a good quality of life. The study presents the authors’ critical opinions and observations about the usefulness of sorafenib in patients with prostate cancer.
Journals System - logo
Scroll to top